NCT06220136 Comparison of the Performances of the cTOFR and the mTOFR During Reversal of Deep Neuromuscular Blockade With Sugammadex
| NCT ID | NCT06220136 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ankara University |
| Condition | Neuromuscular Blockade |
| Study Type | OBSERVATIONAL |
| Enrollment | 199 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 199 participants in total. It began in 2024-06-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
It is known that deep neuromuscular block improves surgical conditions, especially during laparoscopic abdominal surgery. Based on this, in the Perioperative Neuromuscular Blockade Management guide published by the ESAIC association in 2022, it is recommended to deepen the level of neuromuscular blockade in cases where surgical conditions need to be improved. Sugammadex should be used to quickly and reliably reverse deep neuromuscular blockade. TOFScan, a 3-dimensional acceleromyograph for neuromuscular monitoring, has become widely used in recent years. With this monitor, it has been shown that in addition to the classical train-of-four ratio (cTOFR), the modified train-of-four ratio (mTOFR) can be used during the spontaneous recovery of nondepolarizing neuromuscular blockade. In a study conducted by Schmartz et al. in 2021, it was shown that mTOFR, which is the ratio of T4 to the reference stimulus, was compiled later than cTOFR. Therefore, it is suggested that the mTOFR value is a better determinant for safe extubation.
Eligibility Criteria
Inclusion Criteria: * Age: 18 - 65 (not including 65) * BMI: 18.5-24.9 Exclusion Criteria: * Liver and kidney disease * Non-consenting * Emergency surgeries * Muscle disease * Allergy to rocuronium and sugammadex * Patients predicted to have difficult mask ventilation or difficult intubation * Pregnant and breastfeeding women
Contact & Investigator
Menekşe Özçelik, 1
STUDY DIRECTOR
Ankara University
Frequently Asked Questions
Who can join the NCT06220136 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Neuromuscular Blockade. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06220136 currently recruiting?
Yes, NCT06220136 is actively recruiting participants. Contact the research team at htcguness@hotmail.com for enrollment information.
Where is the NCT06220136 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT06220136 clinical trial?
NCT06220136 is sponsored by Ankara University. The principal investigator is Menekşe Özçelik, 1 at Ankara University. The trial plans to enroll 199 participants.